Close Menu


The company will employ its Small Molecule Microarray technology to study drug candidates for new disease targets.

Using its UNIarray protein array platform, the company plans to focus on the development of serum-based protein biomarker tests for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

A recent study combined analysis of a patient's tumor genome and transcriptome sequences to guide treatment of tongue adenocarcinoma with Pfizer's Sutent (sunitinib) and Bayer's Nexavar (sorafenib).

The two firms will evaluate the ability of Protagen's technology for discovering new biomarkers for endometriosis.

Prometheus will develop diagnostic pathway technologies for Bayer Schering Pharma's cancer drug candidates under a deal which could bring in up to $160 million to Prometheus.

The decision paves the way for Enzo to be issued a patent based on its prior application, and the company plans to "rapidly" develop and market products based on the technology for a wide variety of applications.

The patent office was aiming to determine who invented technology first related to nucleic acid signal amplification.

IP Roundup: Jan 12, 2010


Agilent Technologies, Millipore, Bayer, Luminex Molecular Diagnostics, Illumina

The companies will develop and use Genedata's Biologics Data Platform at Bayer Schering R&D sites in Europe and the US.

In addition to biomarker discovery, Kinaxo's PhosphoScout technology will be used to assess the anti-cancer drug Nexavar's effects on cellular phosphorylation patterns.


In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.